Perpetual Ltd Sells 6,384 Shares of argenex SE (NASDAQ:ARGX)

Perpetual Ltd trimmed its holdings in shares of argenex SE (NASDAQ:ARGX - Free Report) by 5.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 114,530 shares of the company's stock after selling 6,384 shares during the quarter. Perpetual Ltd owned about 0.19% of argenex worth $67,786,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. GeoWealth Management LLC increased its position in argenex by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after acquiring an additional 18 shares during the period. Whipplewood Advisors LLC bought a new position in argenex in the 4th quarter valued at about $37,000. Global Retirement Partners LLC increased its holdings in argenex by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after buying an additional 48 shares during the period. FIL Ltd bought a new position in argenex in the 4th quarter valued at about $38,000. Finally, Rakuten Securities Inc. increased its holdings in argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after buying an additional 22 shares during the period. 60.32% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and issued a $720.00 target price on shares of argenex in a report on Tuesday, June 10th. Baird R W raised shares of argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Sanford C. Bernstein raised shares of argenex from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Citigroup restated a "buy" rating on shares of argenex in a research note on Wednesday, May 21st. Finally, Oppenheimer raised their price target on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $729.93.

argenex Trading Down 1.6%

NASDAQ:ARGX traded down $8.92 during mid-day trading on Monday, hitting $551.22. 1,496,036 shares of the company's stock were exchanged, compared to its average volume of 327,359. The company has a 50 day simple moving average of $580.69 and a 200-day simple moving average of $606.71. argenex SE has a fifty-two week low of $428.97 and a fifty-two week high of $678.21. The firm has a market capitalization of $33.66 billion, a P/E ratio of 34.00, a PEG ratio of 1.01 and a beta of 0.39.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. As a group, analysts expect that argenex SE will post 3.13 earnings per share for the current year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.